Antileishmanial effect of cisplatin against murine visceral leishmaniasis

Parasitology International

Volumn 59, Issue 1, 2010, Pages 62-69

  Kaur, Sukhbir ^a   Sachdeva, Heena ^a   Dhuria, Shivani ^a   Sharma, Meenakshi ^a   Kaur, Tejinder ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Antileishmanial activity; Cisplatin; DTH; Visceral leishmaniasis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CISPLATIN; CREATININE; HEMOGLOBIN; MAGNESIUM; PHOSPHORUS; POTASSIUM; SODIUM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; KIDNEY; MAGNESIUM BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CISPLATIN; FEMALE; HYPERSENSITIVITY, DELAYED; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MALE; MICE; MICE, INBRED BALB C; SPLEEN; TREATMENT OUTCOME;

ANIMALIA; MURINAE; MUS;

EID: 76349086675     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2009.10.006     Document Type: Article

References (35)

1. WHO. Report of the fifth consultative meeting on Leishmania/HIV coinfection. Addis Ababa, Ethiopia (2007) 1-32
2. Jha T.K. Drug unresponsiveness and combination therapy for kala-azar. Indian J Med Res 123 (2006) 389-398
3. Kaur S., Ganguly N.K., Sodhi S., Malla N., and Mahajan R.C. Effect of indigenous plant extracts on Leishmania donovani infection in vitro and in vivo, a preliminary report. Immunol Infect Dis 1 (1991) 219-232
4. Kshirsagar N.A., Bodhe P.V., and Kotwani R.N. Targeted drug delivery in visceral leishmaniasis. J Parasit Dis 21 (1997) 21-24
5. Sundar S., and Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res 123 (2006) 345-352
6. Ashutosh, Sundar S., and Goyal N. Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56 (2007) 143-153
7. Sindermann H., and Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100 (2006) S17-S20
8. Merritt R.E., Mahtabifard A., Yamada R.E., Crystal R.G., and Korst R.J. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1609-1617
9. Collins J.L., and Kao M. The anticancer drug, cisplatin increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 29 (1989) 17-22
10. Tavares J., Ouaissi M., Ouaissi A., and Cordeiro-da-Silva A. Characterization of the anti-Leishmania effect induced by cisplatin, an anticancerous drug. Acta Tropica 103 (2007) 133-141
11. Rao R.R., Mahajan R.C., and Ganguly N.K. Modified media for in vitro cultivation of Leishmania promastigotes. A comparative study. PGI Bull 18 (1984) 125-128
12. Yadav M., Nagill R., and Kaur S. Leishmania donovani: effect of pH on the infectivity of axenic amastigotes. J Parasit Dis 28 (2004) 90-95
13. + Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 103 (2008) 1413-1419
14. Bradley D.J., and Kirkley J. Regulation of Leishmania populations within host I. the variable course of Leishmania donovani infections in mice. Clin Exp Immunol 30 (1977) 119-129
15. Nagill R., Mahajan R., Sharma M., and Kaur S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int 58 4 (2009) 359-366
16. Wintrobe M.M. In: Lea, and Febiger (Eds). Clinical hematology. 7th Edition (1975), Philadelphia 114-115
17. WHO. The world health report (2002) 192-197
18. Desjeux P. Focus: leishmaniasis. Nat Rev Microbiol 2 (2004) 692-693
19. Reiner N.E. Host-parasite relationship in murine leishmaniasis: pathophysiological and immunological changes. Infect Immun 38 (1982) 1223-1230
20. Mayrink W., Williams P., da Costa C.A., Magalhães P.A., Melo M.N., Dias M., et al. An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil. Ann Trop Med Parasitol 79 (1985) 259-269
21. Fahey J.R., and Herman R. Relationship between delayed hypersensitivity response and acquired cell-mediated immunity in C57BL/6J mice infected with Leishmania donovani. Infect Immun 49 (1985) 447-451
22. Manson-Bahr P.E. Immunity in kala-azar. Trans R Soc Trop Med Hyg 55 (1961) 550-555
23. de Andrade T.M., Teixeira R., de Andrade J.A., Pereira C., de Carvalho, and Filho E.M. Hypersensitivity of delayed type in visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 24 (1982) 298-302
24. Carvalho E.M., Teixeira R.S., and Johnson Jr. W.D. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 33 (1981) 498-500
25. Durak I., Ozbek H., Karaayvaz M., and Oztürk H.S. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol 25 (2002) 1-8
26. Khynriam D., and Prasad S.B. Hematotoxicity and blood glutathione levels after cisplatin treatment of tumor-bearing mice. Cell Biol Toxicol 17 (2001) 357-370
27. Mathur P., Samantaray J.C., and Samanta P. High prevalence of functional liver derangement in visceral leishmaniasis at an Indian tertiary care center. Clin Gastroenterol Hepatol 6 (2008) 1170-1172
28. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., and Bhattacharya S.K. Injectable paromomycin for visceral leishmaniasis in India. N Eng J Med 356 (2007) 2571-2581
29. Ramadan L.A., El-Habit O., Arafa H., and Sayed-Ahmad M.M. Effect of cremophor-EL on cisplatin-induced organ toxicity in normal rat. J Egypt Natl Canc Inst 13 (2001) 139-145
30. Bogin E., Marom M., and Levi Y. Changes in serum, liver and kidneys of cisplatin-treated rats; effects of antioxidants. Eur J Clin Chem Clin Biochem 32 (1994) 843-851
31. Sueishi K., Mishima K., Makino K., Itoh Y., Tsuruya K., Hirakata H., et al. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur J Pharmacol 451 (2002) 203-208
32. Silkensen J.R., Agarwal A., Nath K.A., Manivel J.C., and Rosenberg M.E. Temporal induction of clusterin in cisplatin nephrotoxicity. J Am Soc Nephrol 8 (1997) 302-305
33. Mavichak V., Wong N.L., Quamme G.A., Magil A.B., Sutton R.A., and Dirks J.H. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28 (1985) 914-921
34. Berns J.S., and Ford P.A. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol 17 (1997) 54-66
35. Sundar S., Jha T.K., Sindermann H., Junge K., Bachmann P., and Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 22 (2003) 434-438